Therapeutic Aspects of Hepatitis C in Hemodialysis Patients

[Guest guest]

http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract & ArtikelNr=\

151633 & Ausgabe=239997 & ProduktNr=223979

Original Report: Patient-Oriented, Translational Research

Therapeutic Aspects of Hepatitis C in Hemodialysis Patients

Seyed Mohammadmehdi Hosseini Moghaddama, Seyed Moayed Alavianb, Mohammad

Rahnavardia

aUrology and Nephrology Research Center (UNRC), Shahid Beheshti University, M.C.

(SBUMS), and

bBaqiyatallah Research Center for Gastroenterology and Hepatology, UNRC,

Baqiyatallah University of Medical Sciences, Tehran, Iran

Address of Corresponding Author

Am J Nephrol 2009;29:123-128 (DOI: 10.1159/000151633)

--------------------------------------------------------------------------------

Abstract

Background: Since hemodialysis (HD) patients usually suffer from multiple

clinical problems and drug side effects, the treatment of hepatitis C in these

patients still remains a challenging problem. Methods: We identified eligible

studies using a wide-spectrum search up to May 2007 in MEDLINE (since 1966) and

EMBASE (since 1980). Two researchers (S.M.H.M. and M.R.) independently reviewed

the manuscripts identified by the search strategy. To determine the most current

information, only studies that had been published after 1995 were included.

Results: Interferon (IFN)- has long been used for this purpose; however, more

recently the advent of pegylated (PEG) IFN has proven to be more beneficial in

these patients. Even though the usage of ribavirin is promising in the case of

hepatitis C in otherwise healthy subjects, the utilization of this drug in

patients with renal failure may be accompanied by catastrophic complications.

Conclusion: Although both conventional IFN and PEG-IFN seem to be favorable

options for the management of hepatitis C in HD patients, further studies on new

therapeutic agents are required.

S. Karger AG, Basel

--------------------------------------------------------------------------------

Author Contacts

S.M. Hosseini Moghaddam, MD

UNRC, No. 44, Boostan 9th St.

Pasdaran Ave.

Tehran (Iran)

Tel. +98 2 122 567 222, Fax +98 2 122 567 282, E-Mail h_sasan@...

--------------------------------------------------------------------------------

Article Information

Received: April 24, 2008

Accepted: June 11, 2008

Published online: August 22, 2008

Number of Print Pages : 6